Immune Checkpoint Inhibitors for Esophageal Cancer

tibbionko-17-1-kapak

Perihan PERKİNa , Gökhan UÇARa
aAnkara Bilkent City Hospital, Clinic of Medical Oncology, Ankara, Türkiye

Perkin P, Uçar G. Immune checkpoint inhibitors for esophageal cancer. In: Şendur MAN, ed. Current Immunotherapy Landscape for Solid Tumors. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.72-6.

ABSTRACT
Esophageal cancer (EC) is the eighth-most common cancer and the sixth-most common cause of cancer releated death worldwide. Esophageal cancer, often diagnosed at an advanced local or metastatic stage when symptoms manifest, demonstrates low cure rates despite multimodal treatment options. For early-stage (Tis, T1a) tumors, endoscopic treatment options can be preferred, whereas for local and locally advanced esophageal cancer, determining the optimal treatment plan requires a multidisciplinary assessment. The positive effectiveness and safety of ICIs were initially shown through single-arm, Phase II clinical trials as salvage monotherapy in patients with advanced esophageal cancer. Following these promising outcomes, direct comparison Phase III clinical trials for each immune checkpoint inhibitor (ICI) against standard chemotherapy were carried out in the secondline treatment setting. With ongoing and upcoming studies, it is anticipated that immunotherapy’s role in treatment will continue to expand, potentially altering the prognosis of esophageal cancer positively in the future.

Keywords: Esophagus cancer; immunotherapy; chemotherapy

Referanslar

  1. Napier KJ, Scheerer M, Misra S. Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112-20. [Crossref]  [PubMed]  [PMC]
  2. Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016;41:88-95. [Crossref]  [PubMed]
  3. Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50-v7. [Crossref]  [PubMed]
  4. Hiramoto S, Kato K, Shoji H, Okita N, Takashima A, Honma Y, et al. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma. Int J Clin Oncol. 2018;23(3):466-72. [Crossref]  [PubMed]
  5. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol. 2019;5(4):546-50. [Crossref]  [PubMed]  [PMC]
  6. Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, et al. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clin Cancer Res. 2018;24(6):1296-304. [Crossref]  [PubMed]
  7. Xu R, Wang F, Xu N, Shen L, Dai G, Yuan X, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study. J Clin Oncol. 2018;36:108. [Crossref]
  8. Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, et al. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022;8(10):1456-65. [Crossref]  [PubMed]  [PMC]
  9. Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942-8. [Crossref]  [PubMed]  [PMC]
  10. Zang YS, Dai C, Xu X, Cai X, Wang G, Wei J, et al. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med. 2019;8(10):4699-708. [Crossref]  [PubMed]  [PMC]
  11. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68-74. [Crossref]  [PubMed]
  12. Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al.; CROSS Study Group. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J Clin Oncol. 2021;39(18):1995-2004. [Crossref]  [PubMed]
  13. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086-92. [Crossref]  [PubMed]  [PMC]
  14. Liu J, Li J, Lin W, Shao D, Depypere L, Zhang Z, et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study. Int J Cancer. 2022;151(1):128-37. [Crossref]  [PubMed]
  15. Shang X, Zhao G, Liang F, Zhang C, Zhang W, Liu L, et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). Ann Transl Med. 2022;10(4):229. [Crossref]  [PubMed]  [PMC]
  16. Shang X, Zhang W, Zhao G, Liang F, Zhang C, Yue J, et al. Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002). Front Oncol. 2022;12:831345. [Crossref]  [PubMed]  [PMC]
  17. Li C, Zhao S, Zheng Y, Han Y, Chen X, Cheng Z, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2021;144:232-41. [Crossref]  [PubMed]
  18. Kato K, Ito Y, Daiko H, Ozawa S, Ogata T, Hara H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. 2022. ASCO Gastrointestinal Cancer Symposium. 2022;40(4_suppl): 238. Abstract #238. [Crossref]
  19. Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol. 2020;16(19):1351-7. [Crossref]  [PubMed]
  20. Matsuda S, Yamamot S, Kato K, Daiko H, Kojima T, Hara H, et al. FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)-short-term results for cohorts C and D. ASCO Gastrointestinal Cancer Symposium. 2022;40(4_suppl): 286. Abstract #286. [Crossref]
  21. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al.; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384(13):1191-203. Erratum in: N Engl J Med. 2023;388(7):672. [Crossref]  [PubMed]
  22. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18(5):631-9. [Crossref]  [PubMed]
  23. Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, et al.; KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol. 2020;38(35):4138-48. [Crossref]  [PubMed]
  24. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506-17. Erratum in: Lancet Oncol. 2019;20(11):e613. [Crossref]  [PubMed]
  25. Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, et al.; RATIONALE-302 Investigators. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. J Clin Oncol. 2022;40(26):3065-76. Erratum in: J Clin Oncol. 2024;42(4):486. [Crossref]
  26. Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al.; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759-71. Erratum in: Lancet. 2021;398(10314):1874. [Crossref]  [PubMed]
  27. Chau I, Ajani JA, Doki Y, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: expanded efficacy and safety analyses from CheckMate 648. J Clin Oncol. 2022;40 Issue 16 Suppl. [Crossref]
  28. Yoon HH, Kato K, Raymond E, Hubner R, Shu Y, Pan Y, et al. RATIONALE-306: Randomized, global, placebo-controlled, double-blind Phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma. Esmo Wgi. 2022;33:S375. Abstract LBA-1. [Crossref]
  29. Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al.; ESCORT-1st Investigators. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021;326(10):916-25. [Crossref]  [PubMed]  [PMC]
  30. Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al.; ORIENT-15 study group. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714. [Crossref]  [PubMed]  [PMC]
  31. Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022;40(3):277-88.e3. [Crossref]  [PubMed]
  32. Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498-509. [Crossref]  [PubMed]
  33. Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021;17(10):1143-53. [Crossref]  [PubMed]  [PMC]